• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 18th December 2017

Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016. The centralised procedure was created in 1995 to facilitate access to innovative medicines across the European Union (EU). Since then…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
CAPs_NHSFunding_2_1200_708-2

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.

The centralised procedure was created in 1995 to facilitate access to innovative medicines across the European Union (EU). Since then the scope of authorisation via the centralised procedure has been broadened and made mandatory for orphan and oncology medicines.

We analysed routine funding in the NHS for new medicines recently authorised via the centralised procedure with a particular focus on oncology and orphan medicines. We utilised a database of outcomes of health technology assessment (HTA) evaluations conducted in the UK by NICE, AWMSG and SMC: OHE’s Medicines Tracker. We considered centrally authorised products (CAP) approved between 1 January 2011 and 31 December 2016.

Our analysis revealed that:

  • NICE evaluated 42% (216) of the 512 new authorisations approved by the European Commission. They recommended 85% of the medicinal products that they evaluated.
  • 378 indications (approximately 75%) were evaluated by the SMC. The SMC recommended 67% of these new medicines.
  • In Wales, the AWMSG initiated 263 evaluations, but did not receive any evidence from companies for nearly 50% (129) of the appraisals. Of the remaining 134 appraisals, 123 products (92%) were recommended by the AWMSG.

Our analysis found that in England and Scotland, products used in oncology and orphan disease were associated with a lower odds of receiving a positive HTA recommendation compared with non-oncology products and products which did not receive an orphan designation in the EU.

An analysis of time elapsed between marking authorisation and the publication of the final HTA recommendation found the median time to be five months in Wales, eight months in Scotland, and 13 months in England. Notably, the evaluation of orphan or oncology medicines, used in therapeutic areas with recognised unmet medical needs, was not consistently prioritised by HTA agencies in the UK. Additionally, we found little agreement in the recommendations resulting from the evaluations completed by AWMSG, NICE and SMC.

The availability of and routine funding of medicines in England according to three main therapeutic classes (oncology, anti-infectives and other) from authorisation via the centralised procedure to access in the NHS is presented in Figure 1.

Figure 1: From authorisation to availability in the NHS in England

Some products are directly commissioned by the NHS and do not go through NICE’s evaluation process. For the period of interest this includes 61 products directly funded by NHS England specialised commissioning. We identified 25 orphan medicinal products that were directly commissioned by NHS England. Additionally despite the fact that the NHS has put several mechanisms in place to grant access to orphan drugs in England, only 60% of the orphan drugs which received a marketing authorisation during the period of our study were accessible to patients in England (this confirms the results of previous OHE research).

The availability of and routine funding of orphan medicines in England from authorisation via the centralised procedure to access in the NHS is presented in Figure 2.

Figure 2: Orphans vs non-orphans, from authorisation to availability in the NHS in England

In summary we find that a substantial number of products which received an EU authorisation between 2011 and 2016 were not referred for a HTA evaluation in the UK. Previous evidence suggests that before 2011 oncology medicines were more likely to receive a positive recommendation than products for the other classes (Dakin et al. 2015). Our study shows that this likelihood has been reversed since 2012.

We also show that there is both variation across agencies and variation across therapeutic classes in terms of adoption decisions and access across the three devolved nations.

Access the full report here.

  • Health Data and Statistics
  • Economics of Innovation
  • NICE

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!